Recent developments and therapeutic strategies against hepatocellular carcinoma

Mark Yarchoan, The Sidney Kimmel Comprehensive Cancer Center
Parul Agarwal, University of Pennsylvania
Augusto Villanueva, Icahn School of Medicine at Mount Sinai
Shuyun Rao, The George Washington University
Laura A. Dawson, University of Toronto
Josep M. Llovet, Icahn School of Medicine at Mount Sinai
Richard S. Finn, David Geffen School of Medicine at UCLA
John D. Groopman, Johns Hopkins Bloomberg School of Public Health
Hashem B. El-Serag, Baylor College of Medicine
Satdarshan P. Monga, University of Pittsburgh Medical Center
Xin Wei Wang, National Cancer Institute (NCI)
Michael Karin, University of California, San Diego
Robert E. Schwartz, Weill Cornell Medicine
Kenneth K. Tanabe, Massachusetts General Hospital
Lewis R. Roberts, Mayo Clinic
Preethi H. Gunaratne, University of Houston
Allan Tsung, The Ohio State University Wexner Medical Center
Kimberly A. Brown, Henry Ford Hospital
Theodore S. Lawrence, University of Michigan, Ann Arbor
Riad Salem, Northwestern University Feinberg School of Medicine
Amit G. Singal, UT Southwestern Medical School
Amy K. Kim, Johns Hopkins University
Atoosa Rabiee, VA Medical Center
Linda Resar, Johns Hopkins University
Yujin Hoshida, UT Southwestern Medical School
Aiwu Ruth He, Georgetown Lombardi Comprehensive Cancer Center
Kalpana Ghoshal, The Ohio State University College of Medicine
Patrick B. Ryan, Janssen Pharmaceuticals, Inc.
Elizabeth M. Jaffee, The Sidney Kimmel Comprehensive Cancer Center
Chandan Guha, Albert Einstein College of Medicine of Yeshiva University
Lopa Mishra, The George Washington University
C. Norman Coleman, National Cancer Institute (NCI)

Document Type

Journal Article

Publication Date

9-1-2019

Journal

Cancer Research

Volume

79

Issue

17

DOI

10.1158/0008-5472.CAN-19-0803

Abstract

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer deaths globally. The landscape of systemic therapy has recently changed, with six additional systemic agents either approved or awaiting approval for advanced stage HCC. While these agents have the potential to improve outcomes, a survival increase of 2-5 months remains poor and falls short of what has been achieved in many other solid tumor types. The roles of genomics, underlying cirrhosis, and optimal use of treatment strategies that include radiation, liver transplantation, and surgery remain unanswered. Here, we discuss new treatment opportunities, controversies, and future directions in managing HCC.

Link to Full Text

Share

COinS